EP1589930A2 — Combination therapy for anticoagulation
Assigned to Individual · Expires 2005-11-02 · 21y expired
What this patent protects
A combination anticoagulation medicament including vitamin K with warfarin in an oral form is described. Between 50 and 5000 milligrams of vitamin K are combined in a single oral medication with 0.5 to 15 milligrams of warfarin for administration. The combination of vitamin K wit…
USPTO Abstract
A combination anticoagulation medicament including vitamin K with warfarin in an oral form is described. Between 50 and 5000 milligrams of vitamin K are combined in a single oral medication with 0.5 to 15 milligrams of warfarin for administration. The combination of vitamin K with warfarin in a single orally dosed form is a novel approach to improving the effectiveness of anticoagulation. The combination allows for broader application of warfarin in medical anticoagulation and reduces the variability of anticoagulation due to the influences of diet, additional medications, nutritional status, changes in physical condition, and potentially other factors. Use of the combination therapy improves the safety of warfarin as an appropriate anticoagulant for many medical conditions.
Drugs covered by this patent
- Vascepa (ICOSAPENT ETHYL) · Amarin Pharms
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.